| Metric | Value ($ M) | Q3 FY25 |
|---|---|---|
| Revenue | 154.45 | 15.0% |
| Total Income | 154.45 | 15.0% |
| Expenditure | 150.10 | 12.0% |
| PBT | 4.02 | 4566.7% |
| Net Profit | 4.06 | 1603.7% |
| OPM | 2.82% | 2.66pp |
| NPM | 2.63% | 2.83pp |
| EPS | 0.08 | 900.0% |
AtriCure Reports Q3 2026 Financial Results with 15% Revenue Growth
04 Nov 2026 · 4 Nov, 2:36 am
Summary
AtriCure, Inc. reported strong third quarter 2026 financial results, with worldwide revenue increasing by 15.0% year over year to $154.5 million. The company saw significant profitability expansion, achieving a net income of $4.1 million and an adjusted EBITDA of $26.8 million, up 51% compared to the third quarter of 2025. Gross margin also improved by 180 basis points to 77.3%. Management expressed confidence in the company's broad portfolio and disciplined execution, highlighting the adoption of innovative technologies as a key driver for growth and profitability.
Key Highlights
- 1
Third Quarter 2026 worldwide revenue reached $154.5 million, marking a 15.0% increase year over year.
- 2
Profitability expanded in the Third Quarter 2026, with net income reported at $4.1 million.
- 3
Adjusted EBITDA for the third quarter 2026 was $26.8 million, an increase of 51% from the prior year period.
- 4
Gross margin improved to 77.3% for the third quarter 2026, up 180 basis points from the third quarter 2025.
- 5
Basic and diluted net income per share was $0.08 for the third quarter 2026, compared to a net loss per share of $0.01 in the prior year.
- 6
Full year 2026 revenue is projected to be approximately $606 million to $610 million.
Management Comments
Michael Carrel
Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution. Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead. We are well positioned to extend our leadership in cardiac surgery and post-operative pain management, creating lasting value for patients and our shareholders.
Informational and educational content only. Not investment advice.